ClinicalTrials.gg
RecruitingNCT05577143BACCHUSUpdated May 22, 2026

Blood Screening for Adult Colorectal Cancer

An observational study in Cancer Colorectal, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by University Hospital, Lille · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
303
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Colonic Neoplasms with a site in France — 49 open to participants now, 66 under way, 13 of them phase 3. Colonic Neoplasms · France.

Planned enrollment
22nd of 55
303 · median 220
Started
2023
with 13 others
Observational
55 of 213
14 open now
Primary completion
2027-03
later than 29 of 65 live
Registered
171st of 213
by date

Among the 213 studies in Colonic Neoplasms with a site in France, this one is the 22nd largest by planned enrollment of the 55 observational ones that give a count, is one of 14 that started in 2023, is one of 55 observational ones, reaches primary completion later than 29 of the 65 other live ones, and was the 171st registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

49 of the 213 studies in Colonic Neoplasms with a site in France are open now. Recruiting first, the newest first:

43 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Colonic Neoplasms with a site in France, or all of them as a file.
02

Study summary

Multicenter, inter-regional, case-control study with the primary objective of evaluating the discriminative power of the blood biomarker TFPI-1 to separate patients with histologically proven CRC from an asymptomatic control population between 50 and 75 years of age with normal colonoscopy.

03

Conditions studied

  • Cancer Colorectal

Keywords

  • Oncology
  • Biology
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients followed up for colonoscopy in the gastroenterology and digestive surgery departments of 5 regional hospitals in northern France

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with suspected colorectal cancer for which colonoscopy is indicated.
  • Patients between 50 and 75 years old, asymptomatic from the digestive point of view (for example referred for colonoscopy as part of a pre-operative check-up of an inguinal hernia or 3 months after an episode of complicated sigmoiditis), for whom a follow-up colonoscopy is indicated.

Note.

  • If the post-inclusion colonoscopy is normal, no will be performed and patients will be assigned to the control group.
  • If the colonoscopy performed after inclusion is abnormal (presence of at least one mucosal lesion), patients will be assigned to the "colorectal cancer" group or to the "polyps" group depending on the results of the anatomopathological analysis of the lesion(s)

Exclusion criteria

Exclusion Criteria:

  • All clinical situations outside of CRC that could increase TFPI-1 or 2 blood levels: acute coronary syndrome (unstable angina, acute myocardial infarction), severe sepsis, decompensated cirrhosis, pregnancy, chronic inflammatory bowel disease (Crohn's or ulcerative colitis), colitis or radiation rectitis.
  • Endoscopic polypectomy without prior histological confirmation.
  • Emergency (occlusion or peritonitis)
  • Minor patients.
  • Persons of full age under legal protection or unable to express their consent
  • Persons not affiliated to a social security system or beneficiaries of such a system.
  • Pregnant women, women in labor or nursing mothers.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
303 participants (estimated)
Patient registry
No

Groups and cohorts

  • Case group

    All consecutive patients from participating centers with an abnormal colonoscopy (presence of mucosal lesions at endoscopy), with histological confirmation of colorectal cancer. These will be patients with one or more histologically confirmed adenocarcinomatous lesions (CRC+) located in the colonic frame or rectum, with or without synchronous liver metastases.

  • Control group

    All consecutive patients between 50 and 75 years of age for whom colonoscopy will be normal (no mucosal lesions). In this situation, histological examination is not performed.

  • Polyp group

    All consecutive patients for whom colonoscopy shows mucosal lesions that will be classified as polyps after histological examination.

06

What researchers measure

Primary outcomes

  1. Area under the ROC curve (AUC) of the TFPI-1 biomarker

    the AUC of the TFPI-1 biomarker to separate the 2 groups (CRC+ and control, i.e., asymptomatic population between 50 and 75 years with normal colonoscopy).

    Time frame: At 2 months

Secondary outcomes

  1. AUC of the TFPI-2 biomarker to separate the 2 groups (CRC+ and control).

    Time frame: At 2 months

  2. AUC of the discriminant score constructed by logistic regression with the 2 blood biomarkers as explanatory variables and the group type (CRC+ and control) as the variable to be explained.

    Time frame: At 2 months

  3. Extension of c-index to the 3-group case proposed by Van Calster B et al.

    Time frame: At 2 months

07

Study locations

1 of 1 sites recruiting
  • Hôpital HURIEZ - Chirurgie digestive et transplantation
    Lille, France
    Recruiting
    • philippe ZERBIB, Pr · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2027, 48 months after the start.

Of 186 non-industry observational studies under Colonic Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 116. This study's planned 48 months is below that.

Counting every sponsor, half of 225 studies reached it within 50 months; a quarter within 27 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2022
First posted
Oct 13, 2022
StartActual
Mar 23, 2023
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05577143
Collaborators
Ministry of Health, France
Responsible party
Sponsor
First posted
Oct 13, 2022
Start date
Mar 23, 2023
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
May 22, 2026

Study contacts

Philippe ZERBIB, MD,PhD
Contact
philippe.zerbib@chru-lille.fr
0320445962 ext. +33
Philippe ZERBIB, MD,PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion